Mailman R, Yang Y, Huang X
Eur J Pharmacol. 2020; 892:173760.
PMID: 33279520
PMC: 7861126.
DOI: 10.1016/j.ejphar.2020.173760.
Boyd K, Mailman R
Handb Exp Pharmacol. 2012; (212):53-86.
PMID: 23129328
PMC: 4711768.
DOI: 10.1007/978-3-642-25761-2_3.
Hasbi A, ODowd B, George S
Mol Brain. 2011; 4:26.
PMID: 21663703
PMC: 3138392.
DOI: 10.1186/1756-6606-4-26.
Kuribara H
Psychopharmacology (Berl). 1994; 116(2):125-9.
PMID: 7862940
DOI: 10.1007/BF02245053.
Lin M, Walters D
Psychopharmacology (Berl). 1994; 114(2):262-8.
PMID: 7838918
DOI: 10.1007/BF02244847.
Inhibition of methamphetamine sensitization by post-methamphetamine treatment with SCH 23390 or haloperidol.
Kuribara H
Psychopharmacology (Berl). 1995; 119(1):34-8.
PMID: 7675947
DOI: 10.1007/BF02246051.
S(-)DP-5,6-ADTN as an in vivo dopamine receptor ligand: relation between displacement by dopamine agonists and their pharmacological effects.
Rollema H, Feenstra M, Grol C, Lewis M, Staples L, Mailman R
Naunyn Schmiedebergs Arch Pharmacol. 1986; 332(4):338-45.
PMID: 3736679
DOI: 10.1007/BF00500084.
The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide.
Brown F, Campbell W, Clark M, Graves D, Hadley M, Hatcher J
Psychopharmacology (Berl). 1988; 94(3):350-8.
PMID: 3128811
DOI: 10.1007/BF00174689.
In vivo receptor binding, neurochemical and functional studies with the dopamine D-1 receptor antagonist SCH23390.
Hjorth S, Carlsson A
J Neural Transm. 1988; 72(2):83-97.
PMID: 2968439
DOI: 10.1007/BF01250232.
Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors.
Jackson D, Hashizume M
J Neural Transm. 1987; 69(1-2):131-45.
PMID: 2953861
DOI: 10.1007/BF01244104.
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.
Braun A, Fabbrini G, Mouradian M, Serrati C, Barone P, Chase T
J Neural Transm. 1987; 68(1-2):41-50.
PMID: 2949059
DOI: 10.1007/BF01244638.
Effects of the putative D-1 antagonist SCH 23390 on stereotyped behaviour induced by the D-2 agonist RU24213.
Pugh M, OBoyle K, Molloy A, Waddington J
Psychopharmacology (Berl). 1985; 87(3):308-12.
PMID: 2934758
DOI: 10.1007/BF00432713.
Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics.
Undie A, Friedman E
Psychopharmacology (Berl). 1988; 96(3):311-6.
PMID: 2906152
DOI: 10.1007/BF00216056.
Blockade of the discriminative stimulus effects of cocaine in rhesus monkeys with the D1 dopamine antagonist SCH 23390.
Kleven M, Anthony E, Goldberg L, Woolverton W
Psychopharmacology (Berl). 1988; 95(3):427-9.
PMID: 2901130
DOI: 10.1007/BF00181961.
Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390.
Serra G, Collu M, Gessa G
Psychopharmacology (Berl). 1987; 91(3):330-3.
PMID: 2882540
DOI: 10.1007/BF00518186.
SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.
Breese G, Mueller R
Eur J Pharmacol. 1985; 113(1):109-14.
PMID: 2864260
PMC: 3056237.
DOI: 10.1016/0014-2999(85)90349-8.
Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
Lappalainen J, Hietala J, Syvalahti E
Psychopharmacology (Berl). 1989; 98(4):472-5.
PMID: 2570432
DOI: 10.1007/BF00441944.
Haloperidol- and SCH23390-induced dopaminergic supersensitivities are not additive in the rat.
Parashos S, Barone P, MARIN C, Paraschos A, Chase T
Psychopharmacology (Berl). 1989; 98(2):189-92.
PMID: 2569216
DOI: 10.1007/BF00444690.
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
Braun A, Mouradian M, Mohr E, Fabbrini G, Chase T
J Neurol Neurosurg Psychiatry. 1989; 52(5):631-5.
PMID: 2567345
PMC: 1032178.
DOI: 10.1136/jnnp.52.5.631.
Yawning and suppression of exploration in amphetamine-treated rats, incompatibility with the autoreceptor hypothesis.
Stahle L, Ungerstedt U
Psychopharmacology (Berl). 1989; 97(4):553-60.
PMID: 2567032
DOI: 10.1007/BF00439563.
